دانلود کتاب Behavioral Pediatrics: Mental Health and Management

فهرست مطالب :

Dedication for this 5th Edition Contents Forewords First edition Second edition Third edition Fourth edition Current fifth edition References Preface References Section one: Special issues (editor: Donald E. Greydanus) Chapter 1 Suicide and self-harm in children and adolescents Abstract Introduction Epidemiology Global suicide rates Suicide in young children Risk factors Previous suicide attempts or self-harm behaviors Gender Sexual orientation Familial factors Stressors Access to lethal means Media and screen time Protective factors Parental supervision Social support Religion Prevention Lethal means restriction School-based programs School personnel training (gatekeeper training) Student education and skills training Suicide risk screening Community-based programs Healthcare-based programs Media related prevention strategies Assessment Treatment Psychotherapy Pharmacological treatments Conclusion References Chapter 2 Psychotic disorders in children and adolescents Abstract Introduction Prodromal phase/Clinical high-risk phase Delusions Hallucinations Disorganized speech Disorganized behavior Negative symptoms Epidemiology Etiology Childhood adversity Genetic vulnerability Pathogenesis Differential diagnosis Substance use disorders (SUD) and drug intoxications Post-traumatic stress disorder (PTSD) Autism spectrum disorders Schizoaffective disorders Mood disorders Medical diseases Nonpsychotic Children Evaluation Approach considerations Consultations Pharmacotherapy Prodromal stage Medications for Prodromal stage Antipsychotics Evidence Omega-3 fatty acids Evidence Antidepressants Evidence Summary First episode psychosis Positive symptoms Negative symptoms Choosing the initial antipsychotic Long-acting injectable (LAI) formulations Evidence Treatment resistant schizophrenia Side effects Second-generation antipsychotics First-generation antipsychotics Side effect differences when compared to adults Treatment of side effects Electroconvulsive Therapy (ECT) Psychosocial interventions Conclusion References Chapter 3 Recognizing and treating the emotional and behavioral effects of child maltreatment Abstract Abbreviations Introduction Extent of the problem Behavioral issues for young children Behavioral issues for adolescents Issues related to the COVID-19 pandemic Evaluation Medical evaluation (Medical history, examination and diagnosis) Skin lesions in physical abuse Sexual abuse Psychological maltreatment Physical and medical care neglect Mental health screening and evaluation PTSD assessment measures for pre-school aged children PTSD assessment measures for school-aged children General assessment measures for youth Mental health screening and PTSD evaluation for adolescents Reporting Treatment Shared treatment components Pharmacologic treatment Empirically supported non-pharmacologic treatment Conclusion References Chapter 4 Mental health and chronic disease: Issues in cardiovascular disease Abstract Introduction Quality of Life Emotional and behavioral difficulties Cognitive and academic impact Quality of life in pediatric heart transplant patients Parental mental health Psychopharmacological considerations in children with CHD/CVD Hypotension, syncope, and rhythm disturbances QTc prolongation and cardiac conduction delays Stimulants and sudden cardiac death Conclusion References Chapter 5 Mental health considerations in renal disease Abstract Introduction Impact on quality of life for the adolescents and families The quality of life experience of the caregiver Common psychiatric disorders in adolescents with renal disease Depression and other mood symptoms Anxiety disorders Cognitive and learning difficulties Psychopharmacology considerations Pharmacodynamics and pharmacokinetics Renal considerations for psychotropic agents Special considerations: Dialysis patients Conclusion References Chapter 6 The pediatric liver: Mental health considerations Abstract Introduction Mental health issues in liver transplantation Medical Adherence in Pediatric Liver Transplant Recipients Psychological factors influencing adherence Identifying barriers to adherence Interventions for improving adherence The transition of care and medical adherence Measuring medication adherence The importance of pre-operative psychological screening Post-operative neuropsychological outcomes and hepatic encephalopathy The emotional well-being of the pediatric transplant patient: Trauma, family stress, health-related quality of life, and the importance of psychological support Multidisciplinary team Health-related quality of life (HRQoL) Wilson’s disease Hepatitis C Metabolic side-effects of psychotropic medications Conclusion References Chapter 7 Behavioral/emotional effects of COVID-19 on children and teens Abstract Introduction COVID-19 in children Changes for families Mental health-general population Disproportionately negative impact Disruption of critical mental health services Pediatrics in pandemia Psychological screening and referral Management of chronic conditions Guidance specific to mental health + general COVID General guidance during a pandemic Specific guidance for mental and behavioral wellness Identifying parental anxiety Conclusion Disclaimer Additional resources: No-cost materials for families and children References Section two: Perspectives of substance use disorders Chapter 8 Neurobiology of substance use disorders Abstract Introduction General concepts Dopamine D1, D5 receptors D2 and D3 receptors Serotonin and norepinephrine Cannabinoid (CB1) receptors γ-Aminobutyric acid (GABA) Glutamate receptors Magnetic resonance imaging (MRI) Neuropharmacology of specific drugs Stimulants Alcohol Opioids Nicotine/tobacco Cannabinoids Conclusion References Chapter 9 Substance use and abuse in adolescents: An overview Abstract Introduction DSM-5 YRBS 2019 Energy drinks Designer drugs Tobacco 2019 YRBS General issues Pharmacologic management Non-nicotine therapy Marijuana (Cannabis) Alcohol 2019 YRBS Alcohol effects Management of alcohol abuse Amphetamines Methamphetamine Cocaine Management of cocaine addiction Opioids Heroin Management of opioid addiction Hallucinogenic drugs Phencyclidine (PCP) Lysergic acid diethylamine (LSD) Tryptamines MDMA (Ecstasy) “Date rape” drugs Flunitrazepam (Rohypnol) Gamma-hydroxybutyrate (GHB) Gamma-butyro-lactone (GBL) Ketamine Inhalants Barbiturates Conclusion Acknowledgment References Chapter 10 Cannabis: Current concepts and conundrums Abstract Introduction Cannabis sativa plant Prevalence Consumption of cannabis (marijuana) Cannabis and other drug use Cannabinoids Endocannabinoid system Medicinal cannabis Synthetic cannabinoids (cannabinoid designer drugs; cannabimimetics) Cannabis lab testing Medical adverse effects Cannabis hyperemesis syndrome Dental effects of cannabis Pulmonary effects Cannabis and cancer Cardiovascular effects Motor vehicle accidents Sports doping Adverse effects: Psychiatric Cannabis and ADHD Cannabis-related psychiatric disorders Cannabis withdrawal syndrome Addiction Cannabis and psychosis Management Pharmacologic therapies Cannabis intoxication Cannabis withdrawal Cannabis-associated psychosis Cannabis use disorder Oxytocin NAC Others Conclusion References Chapter 11 Psychosocial treatments for substance use disorders Abstract Introduction Primary prevention programs Assessment as an intervention Motivational treatments Motivational interviewing Pre-contemplation stage Contemplation stage Preparation stage Action stage Maintenance stage Contingency management and community reinforcement approaches Community reinforcement approach (CRA) Cognitive-behavioral approaches Functional analysis Drug refusal skills (DRS) Relapse prevention (RP) Family interventions Multidimensional family therapy (MDFT) Conclusion References Chapter 12 Substance use disorders in adolescents: Pharmacologic management Abstract Introduction DSM-5 Alcohol Drug interactions Amphetamines Cocaine Opioids Heroin dependence management Conclusion Acknowledgments References Chapter 13 Use of pharmacologic agents for smoking cessation Abstract Introduction Epidemiology Chemistry and pharmacology Effects on health Behavioral approaches to smoking cessation Pharmacological agents Varenicline Bupropion sustained release (SR) Nicotine replacement therapies Second-line medications Vaccine E-cigarettes Conclusion Acknowledgments References Section three: Selective concepts of management (editor: Ahsan Nazeer) Chapter 14 Psychotherapeutic intervention with children and adolescents Abstract Introduction General principles Treatment planning and referral Therapies for depressive disorders Interpersonal therapy Supportive psychotherapy Therapies for anxiety disorders Cognitive-behavioral therapy Therapies for childhood behavioral problems (ADHD, oppositional defiant disorder, and conduct disorder) Parent management training (PMT) Behavioral therapy Parent-child interaction training (PCIT) Behavioral classroom management (BCM) Play therapy Therapies for youth with repeated self-harming behaviors Dialectical behavior therapy (DBT) Therapies for children with autism spectrum disorder Applied Behavior Analysis (ABA) Discrete trial training (DTT) Early intensive behavioral intervention (EIBI) Therapies for eating disorders Family-based treatment (FBT)-Maudsley method Group psychotherapy approaches Conclusion References Chapter 15 Behavioral and cognitive behavioral therapies Abstract Introduction Basic principles Classical conditioning Operant conditioning Types of behavioral therapies Applied Behavioral Analysis (ABA) Discrete Trial Training (DTT) Treatment of the Pivotal Response (PRT) ESDM Cognitive Behavioral Therapy (CBT) CBT in an adolescent with social anxiety disorder-A clinical vignette Pre-treatment assessment Family background Developmental history History of presenting problem Rating Scales Behavioral observations Diagnostic impression Treatment targets Monitoring of treatment targets Description of treatment Sessions 1–2: Decreasing self-focused attention Sessions 3-5: Social skills training Sessions 6-8: Constructing a more realistic image of self in social interactions Sessions 9-11: Exposure in vivo incorporating dropping safety behaviors Session 12: This was the final session Treatment outcome Cognitive-behavioral therapy for psychosis (CBTp) Exposure and response prevention (ERP) Maudsley method-family based treatment (FBT) Phase 1: Weight restoration Phase 2: Return of control to the adolescent Phase 3: Establishing independence and identity Habit reversal therapy (HRT) Conclusion References Chapter 16 Introduction to pediatric psychopharmacology Abstract Introduction Background Antidepressants Selective serotonin reuptake inhibitors Serotonin and norepinephrine reuptake inhibitors Atypical antidepressants Monoamine oxidase inhibitors Tricyclic antidepressants Antipsychotics Pharmacokinetics and pharmacodynamics Side effects Black-box warning Stimulants and non-stimulants FDA approved indications Stimulants and risk of priapism Stimulants and risk of cardiovascular events Stimulants and risk of abuse and dependence Atomoxetine and risk of hepatotoxicity, suicidal ideation, and priapism Conclusion References Section four: Acknowledgements About the editors About the Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine (WMed), Kalamazoo, Michigan, United States of America Contact About Sidra Medicine, Doha, Qatar About the National Institute of Child Health and Human Development in Israel Mission Service and academic activities Research activities National collaborations International collaborations Targets Contact Section five: Index Index Blank Page